Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Englumafusp, an antibody targeting CD19.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Trabikibart, an antibody targeting CSF2RB.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Oberotatug, an antibody targeting LY75.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Evunzekibart, an antibody targeting 4-1BB.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Cemavafusp, an antibody targeting PD-L1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tilatamig, an antibody targeting MET × EGFR.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Eciskafusp, an antibody targeting PD-1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Eurestobart, an antibody targeting ENTPD1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Dalnicastobart, an antibody targeting TNFRSF5.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Anzurstobart, an antibody targeting SIRPA.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Calpurbatug, an antibody targeting Bacteria Proteins HU and IHF.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Xirestomig, an antibody targeting PD-L1 × 4-1BB.